You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Proteasome inhibitor re-sensitizing molecules for treatment of refractory multiple myeloma

    SBC: LEUKOGENE THERAPEUTICS INC            Topic: 102

    Project Summary Abstract Multiple MyelomaMMis the second most common form of blood cancer and remains an incurable and deadly diseaseProteasome inhibitorPItherapy is a cornerstone in the treatment of MMbut resistance to this class of agent is an emerging challenge in the clinicNew therapeutic approaches that specifically target resistance are needed to maximize responses and ultimately produce cur ...

    STTR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  2. IND-Enabling Studies of ZB716, an Orally Bioavailable SERD

    SBC: Zenopharm, LLC            Topic: 102

    Project Summary Fulvestrant is the only FDA approved selective estrogen receptor downregulatorSERDindicated for advanced metastatic breast cancer that has progressed after or during tamoxifen or aromatase inhibitorAItreatmentIn July and Augustfulvestrant was approved as a first line endocrine agent for breast cancer patients by the European Medicines AgencyEMAand US FDArespectivelyHoweverthe drug ...

    SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  3. Novel therapeutic approach in treatment of glioblastoma using sustained delivery of Connxin43 carboxy-terminal peptide encapsulated in biodegradable nanoparticles in combination with temozolomide

    SBC: FirstString Research, Inc            Topic: 102

    PROJECT SUMMARY Glioblastoma (GBM) is an incurable cancer even with aggressive therapies such as surgical resection followed by radiotherapy and chemotherapy using temozolomide (TMZ). Efforts to improve surgical resection or the efficacy of irradiation are limited by the potential damage these interventions cause to the brain. In contrast, sensitizing GBM to TMZ is an appealing strategy because TM ...

    SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  4. Administrative Supplement to Promote Diversity in Research and Development Small Businesses

    SBC: NEUROENE THERAPEUTICS INC            Topic: NINDS

    Abstract Neuroene Therapeutics is a biotech company established to develop and commercialize safe effective therapies for epilepsyinpeople develop epilepsy in their lifetimehowever the currently available anti epileptic drugsAEDshave several issues and liabilities that leave unmet market needssuch asnot controlling seizures forof patients with epilepsycurrent AEDs only treat the symptoms of epilep ...

    SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  5. 4-Demethyl-4-cholesteryloxycarbonylpenclomedine (DM-CHOC-PEN: A Phase II Clinical Trial in Adolescents/Young Adults (AYA)with CNS Malignancies

    SBC: DEKK-TEC INC            Topic: 102

    Abstract – The goal of this Phase II clinical trial application will be to evaluate 4-demethyl-4- cholesteryloxycarbonylpenclomedine (DM-CHOC-PEN) as anticancer therapy for adolescents and young adults (AYA) with cancer involving the brain in a Phase II clinical trial. DM-CHOC-PEN (Fig. 1) is a polychlorinated pyridine cholesteryl carbonate (Fig. 1) that is lipophilic, electrically neural, is ab ...

    SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  6. Simulation Education for Ebola Healthcare Team Competency

    SBC: SIMTUNES            Topic: NCEZID

    Project Summary This product will keep healthcare workers prepared and safe in the next lethal viral pandemic through innovative simulation education. Ebola and other deadly viral diseases represent a major threat to the nation and world. At its peak in December 2015 Ebola had infected 28,640 (including 4 in the U.S.) and killed 11,315 people (including 1 in the U.S.). By the end of 2014 tragicall ...

    SBIR Phase II 2018 Department of Health and Human ServicesCenters for Disease Control and Prevention
  7. Development of an Autism Spectrum Disorder Screening Test based upon Metabolic Profiling of Fresh Blood Samples

    SBC: CIRCA BIOSCIENCE LLC            Topic: 102

    Autism spectrum disorderASDis a neurodevelopmental disorder characterized by significant deficits in reciprocal social interactionsimpaired communication and restrictedrepetitive behaviorswith a prevalence ofinchildren in the USEarly intervention programs have been shown to be effective for improving IQlanguageand social skills for toddlers as young asmonths of ageDiagnosis of ASD is currently bas ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  8. Nucleobase aminosugars with reduced ototoxicity

    SBC: NUBAD LLC            Topic: Y

    PROJECT SUMMARYAminoglycosides are one of the cheapest and well known antibiotics in clinical use for overyearsbut one of the major limitations in their use is their ototoxicityWe are developing fast and low cost methods to develop aminoglycosides with antiribosomal activities and reduced toxicityIn this projectwe will identify novel aminoglycoside antibacterialsthat show reduced ototoxicityComple ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  9. Evaluation of oral oleocanthal to prevent and/or treat Alzheimer's disease and related dementias

    SBC: Oleolive, Inc.            Topic: NIA

    PROJECT SUMMARY Alzheimer s diseaseADis a progressive neurodegenerative disorder of the elderly that afflicts aboutmillion patients globally and overmillion Americans in the USDespite the considerable research effort to preventtreator cure the diseaseeffective strategies remain lackingThe accumulation of amyloidAin the brain blood vessels can result in the development of cerebral amyloid angiopath ...

    SBIR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  10. Emodin as a complementary dietary therapy to reduce toxicity of 5 fluorouracil

    SBC: AcePre, LLC            Topic: NCCIH

    PROJECT SUMMARYfluorouracilFUhas been the first choice chemotherapy drug for colorectal cancerCRCfor many yearshoweverits clinical utility remains hindered by hematopoietic and gastrointestinal toxicities resulting from its non selectivitySide effects include fatigueloss of appetiteand diarrhea among othersall of which can lead to reduced quality of lifeThe economic burden associated with chemothe ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government